Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : World Heart Corp - WHRT and TSE/WHT -- Ignore unavailable to you. Want to Upgrade?

To: William Marsh who wrote (441)	6/13/2000 3:26:00 PM
From: Dan Hamilton	Read Replies (1) \| Respond to of 500

Bill, I don't disagree with your points either, although the elimination of a competitor is the weakest of the points, since Novacor was many years away from their "next generation" device. I believe there can be a case made for both points of view. I believe there are many things in this deal that have strengthened WHT, but that cannot dispel the nagging doubts about their ability to get to human trials AND successfully complete them. Furthermore, one wonders whether the company was overly optimistic in their original schedule. They may have saved themselves the loss of credibility had they not laid out such an aggressive (unrealistic?) timeline to begin with. Although they seemingly have made great strides in the past year, this is still a highly speculative stock and should be treated as such IMO.

To: William Marsh who wrote (441)	6/13/2000 3:48:00 PM
From: the Chief	Respond to of 500

I don't disagree either Bill. You ave made some very valid points. However, the fact is that Heartsaver has been "ready for trials now for over 2 years" and consistently fails to make any headway. The battery failure issue was "interesting" in that it was explained as a bad battery, yet we redesigned the supporting electronics in Heartsaver??? Now the blood bag that was "more than acceptable" and was utilized during the calf trials all of a sudden becomes unacceptable?? you said: 4. A significant improvement to their lead product (the blood bag). 5. A simpler pathway to regulatory approval (due to the approved status of the blood bag). The interesting thing about this is we were told that "NO" component of heartsaver was not already approved for human implant. That is to say, every material presently used in Heartsaver was already approved for use in the Human body. We were all told this "over a year ago". So the fact that the blood bag is "approved" poses no relevance to heartsaver IMHO. When you are looking for approval of an experimental device, such as this, the breakdown of the materials used is cross matched to the materials already approved. Their use within the unit is then looked at for approval. So WHT's bloodbag was already made of a material that was "approved" for insertion in a body. The securing device used to secure the blood bag to the heartsaver is not, the material it is made of, is. So in the longterm the bag may be of better quality and that is why it was chosen....or our bag was crap and the only way they could get another bag was pull a "Remmington"....buy the company! So for some of us longtermers, this stock is no farther ahead than where it was over 1.5 years ago......on the verge of calf trials. Heard it before....this time I'll wait till they are actually "doing something" that proves they are in a "pre-production unit", not some continually changing prototype that changes with every new piece of kit that comes on the market. This said, I believe Heartsaver willbe the stock to own in the future, if they can get their act in gear, I would just like to know I was going to be alive when they finally get to human trials! the Chief